HomeLBank Stocks
Adagene Inc
Adagene Inc

Adagene Inc (ADAG)

24HHigh$1.9524HLow$1.48
$1.79
+0.21%

Last updated: 2026-11-19 10:09:59

K-Line Chart, actual market data is subject to the trading page.

Key Data

Prev. Open
$1.48
Prev. Close
$1.79
Prev. Day's Range
$1.48 - $1.95
52W Range
$1.27 - $4.85
Trading Volume
764.449K
MC
$99.372M
P/E Ratio
--
EPS
$-0.37

Company Overview

NASDAQ

Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
HeadquartersBUILDING C14, SUZHOU, CHINA, 215123
CountryUSA
Listing Date2021-02-09
Fiscal Year Ended2026-06-30
Shares Outstanding67.143M
CIK Code1818838

Financial Metrics

Indicator2026-06-302026-03-312025-06-302024-12-31
Income$1.623M$7.693M--$103.204K
Operating Expenses$256.457K$282.32K$300.326K$926.248K
Net Income-$16.413M-$4.144M-$13.51M-$24.918M
Net Profit Margin-1011.1%-53.9%---24144.7%
Earnings Per Share--------
EBITDA-$16.365M-$5.484M-$15.426M-$22.703M
Effective Tax Rate0.4%6.7%-0.0%0.1%

FAQ

Aditxt, Inc. (TICKER: ADAG) operates in the biotechnology sector, specializing in developing and commercializing immune monitoring and modulation technology. Its core focus is on enhancing immune system control, which includes applications in autoimmune diseases, organ transplantation, and immunotherapies.
ADAG's revenue model is primarily driven by the commercialization of its proprietary immune-monitoring platform and partnerships with healthcare providers, research institutions, and pharmaceutical companies. Licensing deals and collaborations for therapeutic applications represent potential revenue avenues for the company.
ADAG distinguishes itself through its patented immune modulation and monitoring technology, focusing on addressing immune-related conditions such as autoimmune diseases and organ transplant rejection. This approach provides a unique position compared to other general biotechnology firms primarily focused on drug manufacturing.
Key risks for ADAG investors include its reliance on early-stage biotechnology development, potential delays in product commercialization, regulatory hurdles, and competition from established biotech companies. Financial sustainability and funding requirements are also critical factors to consider in this growing sector.
Currently, ADAG does not pay dividends to shareholders. Biotechnology companies like ADAG often reinvest earnings into research and development to advance their proprietary technology and expand their market reach, which remains a priority over distributing profits to shareholders.
ADAG has significant growth opportunities in the rapidly expanding fields of immune health, personalized medicine, and organ transplantation. Its focus on innovative immune modulation technology could position it as an attractive partner for healthcare providers and pharmaceutical companies seeking advanced solutions.
ADAG's valuation reflects its position as a developing biotech company with early-stage revenue potential. Investors often compare such companies based on their proprietary technology, market potential, and investment in research relative to competitors’ market capitalization and financial health.
ADAG faces challenges related to demonstrating clinical efficacy, securing regulatory approvals, and establishing market adoption of its immune modulation technology. Additionally, the company needs funding to sustain long-term R&D initiatives while competing with established biotechnology firms in similar niches.
Risk Warning
  1. 1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
  2. 2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
  3. 3.The information contained on this page is for reference only and does not constitute any investment advice.